Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhIL-15 + Avelumab in T-cell Malignancies
NCT03905135Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2019
- Primary completion
- Mar 2021
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of recombinant human interleukin-15 in peripheral T-cell lymphoma (PTCL), mycosis fungoides (MF), Sézary syndrome (SS) and 1 more (2 arms), sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jun 2019; status: completed.
02
Drugs
recombinant human interleukin-15
03
Conditions
peripheral T-cell lymphoma (PTCL)mycosis fungoides (MF)Sézary syndrome (SS)anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on NCT03905135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03905135.